A phase II study of neoadjuvant chemotherapy plus tremelimumab and durvalumab in advanced-stage ovarian cancer
Trial Number
NCT03899610 (ClinicalTrials.gov Identifier)Contact Person
Status
Closed to Recruitment
Disease Site
Ovarian
Lead Cooperative Group
Participating Groups
GCGS